We hypothesized that prognostic biomarkers for identifying patients that may progress to BCR are present even at the early stage prostate cancer and they could be identified from gene expression profiles of prostatectomy specimens from such a patient cohort. This evidence concerns the gene BCR and Familial prostate cancer.